
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 12, 2026, 4:15 PM ET
Prime Medicine closed its public offering of 41,071,428 shares at $3.50 per share, including full exercise of the underwriters' option for 5,357,142 shares.
U.S. listed: $PRMEBiotech · Gene editingExecution and funding risksOffering closed at $3.50 · November 12, 2026
PRME Stock Hub: Prime Medicine News, Prime Editing and Liver Programs
On November 12, 2026, Prime Medicine closed its underwritten public offering of 41,071,428 shares at $3.50, including the full exercise of the underwriters’ option for 5,357,142 shares, for gross proceeds of about $143.7 million and net proceeds of about $134.7 million. The same day it reported third-quarter results: $61.2 million of cash, cash equivalents and short-term investments at September 30, excluding $13.7 million of restricted cash, and pro forma resources of about $209.5 million including the net proceeds and restricted cash. It guides funding through 2027, while its Form 10-Q still reports substantial doubt about going concern. Prime Medicine enters its next clinical stage with FDA clearance for both liver programs, a human proof of concept in a different disease, and a cash balance that makes financing part of the investment story. The September 24, 2026 announcement cleared PM647 for a US trial; the July 23 announcement did the same for PM577a. Initial liver data are company targets for 2027, while the August 6 update targeted a PM359 biologics application in the first half of 2027. These are distinct milestones with different requirements. Trial permission is not human efficacy, and a planned application is not regulatory acceptance.
Full research report · PDF
Prime Medicine ($PRME), research updated November 13, 2026
17 pages. On November 12, 2026, Prime Medicine closed its underwritten public offering of 41,071,428 shares at $3.50 , including the full exercise of the underwriters’ option for 5,357,142 shares, for gross proceeds of about $143.7 million and net proceeds of about $134.7 million. The same day it reported third-quarter results: $61.2 million of cash, cash equivalents and short-term investments at September 30, excluding $13.7 million of restricted cash, and pro forma resources of about $209.5 million including the net proceeds and restricted cash. It guides funding through 2027, while its Form 10-Q still reports substantial doubt about going concern. Prime Medicine enters its next clinical stage with FDA clearance for both liver programs, a human proof of concept in a different disease, and a cash balance that makes financing part of the investment story. The September 24, 2026 announcement cleared PM647 for a US trial; the July 23 announcement did the same for PM577a. Initial liver data are company targets for 2027, while the August 6 update targeted a PM359 biologics application in the first half of 2027. These are distinct milestones with different requirements. Trial permission is not human efficacy, and a planned application is not regulatory acceptance. This is dated research; the hub follows later developments. For personal use only: redistribution prohibited.
Next company-guided milestones
2027 · initial PM577a and PM647 clinical data · H1 2027 · PM359 BLA submission target
As of November 16, 2026, Prime Medicine had not announced another dated event. Chief Executive Officer Allan Reine, M.D., was scheduled to take part in a fireside chat at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026, at 4:00 p.m. GMT (11:00 a.m. ET), with a live audio webcast on the company website and a replay planned for 90 days. It was an investor-conference appearance, not a data release. Company release
Financing closed: on November 12, 2026 Prime Medicine closed the underwritten public offering priced on November 10: 41,071,428 shares of common stock at $3.50, including the full exercise of the underwriters’ option to buy 5,357,142 additional shares, for gross proceeds of about $143.7 million before underwriting discounts, commissions and offering expenses and net proceeds of about $134.7 million. Jefferies, TD Cowen and Goldman Sachs acted as joint book-running managers; Oppenheimer & Co. and LifeSci Capital as passive book-running managers. Third-quarter release · Pricing release · Final prospectus supplement · September 30 Form 10-Q
Next company milestones: initial PM577a and PM647 clinical data are expected in 2027, and a PM359 BLA submission is targeted for H1 2027; these are separate company forecasts, not a PDUFA or approval date. Primary source Company-guided windows remain forecasts; completed events are dated separately from the next operating or financial disclosure.
PRME stock at a glance
Chart analysis · JC
Technical chart analysis of $PRME with bull and bear scenarios on JC Just Charts.
Unrestricted liquidity · Sept. 30
$61.157M
Form 10-Q: $54.886M cash and equivalents plus $6.271M short-term investments; excludes $13.691M restricted cash; company pro forma ~$209.5M with November net proceeds and restricted cash ·
Historical monthly burn
~$13.382M
Nine-month 2026 operating cash use of $120.439M divided by nine; ~$13.959M in H1 (Merlintrader arithmetic) ·
Management runway
Through 2027
November 12, 2026 guidance, including about $134.7M of November net offering proceeds; the 10-Q still reports going-concern doubt ·
Company common shares
181.921M
October 31, 2026 Form 10-Q cover; excludes the 41,071,428 shares issued in the November offering ·
PM359 filing target
H1 2027
August 6, 2026 company BLA objective, reiterated November 12 (third-quarter release) ·
Liver initial data
2027
PM577a July 23; PM647 September 24 ·
Short interest
29.15M
Nasdaq, October 30, 2026 settlement; 4.80 days to cover ·
Where Prime Medicine stands now
On November 12, 2026, Prime Medicine closed the underwritten public offering it had announced and priced on November 10: 41,071,428 shares of common stock at $3.50, including the full exercise of the underwriters’ option to buy 5,357,142 additional shares, all sold by the company. Gross proceeds were about $143.7 million and net proceeds about $134.7 million, after underwriting discounts, commissions and offering costs of about $9.1 million. The prospectus supplement says the company intends to use the net proceeds, together with existing cash, primarily to advance its Wilson disease and AATD programs and other research and development, and the remainder for working capital, capital expenditures and general corporate purposes. The same day the company reported third-quarter results: $54.886 million of cash and cash equivalents and $6.271 million of short-term investments at September 30, 2026, or $61.157 million of unrestricted liquidity, plus $13.691 million of restricted cash; a quarterly net loss of $39.0 million, versus $50.6 million a year earlier, with R&D expenses of $34.1 million and G&A of $10.0 million; and nine-month operating cash use of $120.439 million. Including the net offering proceeds, the company puts pro forma cash, cash equivalents, investments and restricted cash at about $209.5 million and expects its resources to fund operating expenses and capital expenditures through 2027. The Form 10-Q nevertheless states that management concluded substantial doubt exists about the company’s ability to continue as a going concern for twelve months from the issuance of the financial statements. Its cover reports 181,921,405 shares at October 31, 2026, before the 41,071,428 shares issued in November. Third-quarter release · September 30 Form 10-Q · Pricing release · Final prospectus supplement · Underwriting agreement (Form 8-K)
Prime Medicine enters its next clinical stage with FDA clearance for both liver programs, a human proof of concept in a different disease, and a cash balance that makes financing part of the investment story. The September 24, 2026 announcement cleared PM647 for a US trial; the July 23 announcement did the same for PM577a. Initial liver data are company targets for 2027, while the August 6 update targeted a PM359 biologics application in the first half of 2027. These are distinct milestones with different requirements. Trial permission is not human efficacy, and a planned application is not regulatory acceptance.
Execution and funding. The adverse case combines weak or delayed clinical progress with unfavorable access to capital. In the September 30, 2026 financial statements, nine-month operating cash use of $120.439 million implies a historical monthly burn of approximately $13.38 million (Merlintrader arithmetic). This is a calculated historical average, not a forecast; it nonetheless shows why a delay in a 2027 data window could matter financially. The $13.691 million of restricted cash reported separately at September 30 cannot simply be added to unrestricted development funding.
The constructive case
The favorable case requires credible human activity and tolerability from the liver programs, progress toward the PM359 application, and enough capital to reach those events on workable terms. PM647 and PM577a could show that Prime Editing can address disease inside the body, beyond the edited stem cells used for PM359. The September 24 and July 23 releases place the first liver readouts in 2027; success would require patient data that support the biology and a safety profile compatible with further dosing. Neither IND clearance supplies that evidence by itself. The offering closed on November 12 with the underwriters’ option exercised in full, adding about $143.7 million of gross and $134.7 million of net proceeds; the company now guides funding through 2027.
The cautious case
The adverse case combines weak or delayed clinical progress with unfavorable access to capital. In the September 30, 2026 financial statements, nine-month operating cash use of $120.439 million implies a historical monthly burn of approximately $13.38 million (Merlintrader arithmetic). This is a calculated historical average, not a forecast; it nonetheless shows why a delay in a 2027 data window could matter financially. The $13.691 million of restricted cash reported separately at September 30 cannot simply be added to unrestricted development funding. The offering closed on November 12 at $3.50, and added 41,071,428 shares including the full underwriter option, about 22.6% of the 181.921 million shares reported at October 31 (Merlintrader arithmetic). The September 30 Form 10-Q still reports substantial doubt about going concern.
Latest Prime Medicine news
Nov 12, 2026
Prime Medicine Announces Closing of Public Offering and Full Exercise of Underwriters' Option
Prime Medicine closed its underwritten public offering of 41,071,428 shares of common stock at a public offering price of $3.50 per share. The offering included the full exercise of the underwriters' option to purchase 5,357,142 additional shares. Gross proceeds to Prime Medicine were approximately $143.7 million, before underwriting discounts, commissions and offering expenses.
Nov 12, 2026
Prime Medicine reports third quarter 2026 financial results and provides business updates
Prime Medicine reported a net loss of $39.0 million for the third quarter of 2026, compared with $50.6 million for the same quarter of 2025. R&D expenses were $34.1 million versus $44.0 million, and G&A expenses were $10.0 million versus $11.2 million. Cash, cash equivalents, investments and restricted cash were $74.8 million as of September 30, 2026, and pro-forma cash was approximately $209.5 million, with cash runway through 2027. The company dosed the first patient in its Phase 1/2 trial of PM577a in Wilson disease and received FDA clearance of its IND for PM647 in Alpha-1 Antitrypsin Deficiency.
Nov 10, 2026
Prime Medicine Announces Pricing of Public Offering of Common Stock
Prime Medicine priced an underwritten public offering of 35,714,286 shares of its common stock at a public offering price of $3.50 per share. Gross proceeds are expected to be approximately $125.0 million, excluding any exercise of the underwriters' option to purchase up to an additional 5,357,142 shares. The offering is expected to close on or about November 12, 2026, subject to customary closing conditions.
Nov 10, 2026
Prime Medicine estimates $61.2 million cash as of September 30, 2026
Prime Medicine announced preliminary unaudited estimates of approximately $61.2 million in cash, cash equivalents, and short-term investments as of September 30, 2026, excluding restricted cash of approximately $13.7 million. The company has not yet completed its quarter-end financial close, and the estimates are subject to change. Complete results will be included in its Form 10-Q for the quarter ended September 30, 2026. The company also posted an updated corporate presentation to its website.
Nov 10, 2026
Prime Medicine announces proposed $125.0 million public offering of common stock
Prime Medicine has commenced an underwritten public offering of $125.0 million of its common stock. The company also intends to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares. Jefferies, TD Cowen and Goldman Sachs & Co. LLC are acting as joint book-running managers. The offering is subject to market and other conditions, and there can be no assurance as to whether or when it may be completed.
Oct 28, 2026
FDA draft guidance on individualized genome editing products: one BLA for patient-specific variants, comments open until November 27
On October 27, 2026 HHS announced that the FDA has issued a draft guidance for industry, “Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management”; the notice of availability was published in the Federal Register on October 28 (document 2026-21954, docket FDA-2026-D-11783). The draft gives recommendations on how an individualized genome editing product that includes multiple product variants can be submitted in a single Biologics License Application (BLA), how to specify the extent of variation in the editing component, and how to add new variants to the BLA after licensure. HHS describes the central concept as an “Individualized Feature Space”: predefined boundaries within which a product can vary from patient to patient while remaining under one BLA. According to HHS, a new patient-specific variant that falls inside those boundaries and is supported by laboratory assays showing adequate safety and activity could be added to the license through a streamlined review that relies on the data behind the original approval, without new clinical trials. The draft also touches on potency and safety evaluation, manufacturing process validation, labeling and product naming. The document is a draft: when finalized it will represent the FDA’s current thinking, and the notice states that it does not establish rights for any person and is not binding on the FDA or the public. Comments can be submitted until November 27, 2026. Separately, CMS announced that it plans to extend its Cell and Gene Therapy Access Model beyond sickle cell disease and will issue a request for applications in the coming months. Neither the HHS announcement nor the Federal Register notice names any company or product, and neither approves or favors a specific therapy. Why it matters for Prime Medicine: the company develops Prime Editing candidates, including the liver programs PM577a (Wilson disease, H1069Q mutation) and PM647 (alpha-1 antitrypsin deficiency) and PM359, for which it targets a BLA in the first half of 2027. None of these programs is described by the company as an individualized product, and the draft guidance does not refer to them; it is context on how the FDA is thinking about regulating editing products whose editing component varies. It changes no date, requirement or review timetable for any Prime Medicine program. HHS announcement Federal Register notice
PRME stock catalysts and company milestones
- November 10, 2026 · Offering priced — 35,714,286 shares of common stock at $3.50, for about $125.0 million of gross proceeds before fees, plus a 30-day underwriter option for up to 5,357,142 additional shares; the final prospectus supplement filed on November 12 confirms these terms and estimates net proceeds of about $117.1 million, or about $134.7 million with the full option. Completed · pricing release · final prospectus supplement
- November 12, 2026 · Offering closed — 41,071,428 shares at $3.50, including the full exercise of the underwriters’ option for 5,357,142 shares; about $143.7 million gross and $134.7 million net proceeds. Completed · third-quarter release
- November 12, 2026 · Third-quarter results — $61.157 million of unrestricted cash and investments at September 30, pro forma about $209.5 million with the offering; funding guided through 2027; Form 10-Q still reports going-concern doubt. Completed · Form 10-Q
- November 16, 2026 · 11:00 a.m. ET — Fireside chat with Chief Executive Officer Allan Reine, M.D., at the Jefferies Global Healthcare Conference in London (4:00 p.m. GMT), scheduled with a live audio webcast on the company website and a 90-day replay; an investor appearance, not a data release. Completed · investor conference · company release
- 2027 clinical data; H1 2027 filing target — Initial PM577a and PM647 clinical data are expected in 2027. PM359 BLA submission is targeted for H1 2027; these are separate company forecasts, not a PDUFA or approval date. Company guidance reiterated November 12, 2026
What Prime Medicine is trying to establish
Allan Reine succeeded Keith Gottesdiener as CEO on May 19, 2025, when Jeff Marrazzo became Executive Chair. Svetlana Makhni’s CFO appointment was approved April 7, 2026 and became effective April 16; Reine then ceased serving as principal financial officer while remaining CEO. Prime Medicine SEC filing, April 7, 2026. Prime Medicine press release on strategic restructuring.
Prime Medicine is developing genetic medicines using Prime Editing, which seeks to correct a targeted DNA sequence without the double-strand break used by some other editing approaches. The company is pursuing both cells edited outside the body and delivery into a patient's tissues. Those approaches share technology but require their own clinical evidence. PM359's result is relevant to platform credibility; it cannot substitute for PM647 or PM577a patient data.
Cash, burn and the difference between runway and arithmetic
At June 30, 2026, Prime held $47.451 million of cash and equivalents and $47.620 million of short-term investments, for $95.071 million of unrestricted liquidity. Another $13.691 million was restricted. Adding all three produces the approximately $108.8 million headline balance in the August 6 release, but the unrestricted amount is the appropriate starting point for a simple operating runway calculation.
Operating activities used $83.756 million in the six months ended June 30, 2026. Dividing by six gives approximately $13.959 million per month. Dividing unrestricted June liquidity by that historical rate gave approximately 6.8 months from the June 30 balance-sheet date. That static calculation on June figures, not a prediction of when the company would exhaust cash, has been superseded by the September 30 balance and by the closing of the November 12 offering.
On November 10, 2026 Prime Medicine had estimated cash, cash equivalents and short-term investments of approximately $61.2 million at September 30, excluding restricted cash of approximately $13.7 million; the September 30 Form 10-Q, filed November 12, confirmed $61.157 million. The $125.0 million offering announced on November 10 and priced that evening at $3.50 a share was not included in that figure; it closed on November 12, 2026 with the underwriters’ option exercised in full, for about $143.7 million gross and $134.7 million net. November 10 Form 8-K
The September 30 Form 10-Q, filed November 12, confirms $54.886 million of cash and cash equivalents and $6.271 million of short-term investments, $61.157 million in total, plus $13.691 million of restricted cash. Operating activities used $120.439 million in the first nine months of 2026, about $13.38 million a month, and $36.683 million in the third quarter alone (Merlintrader arithmetic). Including the November net proceeds, the company guides funding through 2027; the 10-Q still concludes that substantial doubt exists about its ability to continue as a going concern for twelve months. September 30 Form 10-Q · Third-quarter release
Prime Medicine deep dive: the full analysis
The chapters below take the company apart: the technology and why it is harder to deliver than to describe, the three clinical programs and what each would have to prove, the November 2026 financing and what it changed, the accounts, the cash position and the capital structure, and the risks that a platform company carries before its first approved product. The same research is available as a downloadable PDF in the Research Library. The Merlintrader Research Library collects our dated biotech stock research reports.
01 Three scenarios: the platform is proven in cells, the question is inside the body
Bull case — the liver programs put edited genes into patients and the data hold
Prime Medicine has already shown that Prime Editing can be done in cells taken out of a patient: PM359, its ex vivo program in chronic granulomatous disease, has a Phase 1/2 study, a Regenerative Medicine Advanced Therapy designation granted in June 2026, and a company target of a biologics license application in the first half of 2027. What the bull case adds is the harder half. PM577a in Wilson disease and PM647 in alpha-1 antitrypsin deficiency deliver the editing machinery into the liver with a lipid nanoparticle, and both programs cleared their investigational new drug applications during 2026; the first patient was dosed in the PM577a Phase 1/2 study in October 2026. If those studies show correction of the target variant with a safety profile that allows repeat dosing, the company moves from one edited-cell product to a platform that can be pointed at other liver genes with the same delivery. That is the scenario in which the November financing buys time rather than just money. Form 10-Q, September 30, 2026
Base case — evidence arrives in 2027, and another financing arrives with it
The realistic path is narrower. Initial clinical data for PM577a and PM647 are company targets for 2027, and a biologics application for PM359 is a first-half 2027 objective. None of those is an efficacy result yet. In this scenario the company reaches 2027 with the roughly $209.5 million of pro forma resources it described on November 12, reports data that are encouraging but early, and raises again before the second half of 2027 because a Phase 1/2 in two liver diseases plus a filing consumes cash faster than a single program. The stock trades on data timing rather than on revenue, and each announcement of a dose escalation or a cohort completion moves it more than the underlying science justifies. Form 10-Q, September 30, 2026
Bear case — delivery or immunogenicity limits the platform to edited cells
The adverse path is the one that matters most for a platform story. In vivo editing requires a lipid nanoparticle to reach the right cells, an editor to be expressed long enough to edit and short enough not to be attacked, and an immune system that tolerates the whole assembly. Those are the reasons the field has produced more mouse data than human data. If either liver study shows transient or sub-therapeutic editing, or a safety signal that prevents the repeat dosing a chronic disease would need, the investable case collapses back to PM359, a single ex vivo product in a very small indication, against a cost base built for a platform. The November offering would then have funded the trial that disproves the thesis. Jiang et al., Nature Nanotechnology 2026
What would falsify this reading
Prime Medicine’s technology risk has moved from the editing reaction to the delivery step, so the reading depends on the delivery question being answered in patients. Four observations would weaken it.
Human liver data showing editing frequencies in the low single digits, well below what a therapeutic effect in Wilson disease or alpha-1 antitrypsin deficiency would require, would indicate that the delivery rather than the editor is the limit. A safety event attributed to the lipid nanoparticle or to the editor protein, particularly one that recurs on redosing, would remove the chronic-dosing model on which both liver programs depend. A delay of the PM359 application beyond the first half of 2027 would undercut the one program that has human data, and with it the near-term credibility of the platform. Finally, a financing before the 2027 readouts at a price below the November offering would show that the market is not willing to carry the company to its own data on the terms it just set. Form 10-Q, September 30, 2026
02 What Prime Medicine does: search and replace, without cutting both strands
Prime Editing is a genome-editing method described by Anzalone et al. in Nature in 2019 as search-and-replace editing without double-strand breaks or donor DNA. Anzalone et al., Nature 2019 The distinction matters clinically. Techniques that cut both DNA strands rely on the cell’s repair machinery to close the break, and the repair can produce insertions, deletions or rearrangements; Prime Editing writes a new sequence directly using a reverse transcriptase fused to a Cas nickase and a prime editing guide RNA. In principle it can correct a single base, insert a few bases or delete a few, without the double-strand break.
Prime Medicine’s own description of its work is that it is developing genetic medicines for diseases driven by defined genetic alterations, acquired cellular dysfunction or dysregulated gene expression, and that it pursues both cells edited outside the body and delivery into a patient’s tissues. The company’s filings separate the two because they carry different risks: an ex vivo product is edited under controlled conditions, checked, and returned, while an in vivo product depends on a delivery vehicle reaching the target organ. Those approaches share the editor and require their own evidence. Form 10-Q, September 30, 2026
The delivery decision is what shapes the current pipeline. The company uses what it calls a universal liver lipid nanoparticle, a formulation intended to carry different editor payloads to the same organ. That modularity is the commercial argument: one delivery system, many genes. It is also the single point of failure, because if the liver nanoparticle does not produce durable editing in patients, the modularity produces nothing. The published literature on in vivo prime editing with lipid nanoparticles gives reason for both optimism and caution; the 2026 work by Jiang et al. reported efficient editing in vivo and in vitro with lipid nanoparticles, Jiang et al., Nature Nanotechnology 2026 while other groups have focused on RNA motif modifications precisely because efficiency in animals has been uneven. Lei et al., Nature Biomedical Engineering 2026
03 PRME stock catalysts: three programs, three different kinds of proof
The company’s dated or guided milestones are not interchangeable, and reading them as one calendar is the most common mistake made about this stock. PM359 needs a biologics license application in the first half of 2027, which requires the chronic granulomatous disease study to mature and the manufacturing and analytical work to be complete. PM577a and PM647 need initial clinical data in 2027 from two separate Phase 1/2 studies. The first is a filing milestone built on data that already exist in part; the others are first-in-human readouts in a new delivery modality. Form 10-Q, September 30, 2026
A pass on PM577a would mean measurable correction of the H1069Q variant in liver tissue with a safety profile that supports continued dosing. In a first-in-human study the company may report biomarker or biopsy data rather than clinical benefit, and a copper-related endpoint is more informative than a sequence-level edit alone. A pass on PM647 would mean correction of the E342K, or Pi*Z, variant in the SERPINA1 gene with acceptable tolerability; the clinical question is whether corrected protein production reaches a level that changes the disease course, which is a higher bar than detecting editing. Form 10-Q, September 30, 2026
For PM359 the milestone is a filing, not an approval, and the difference should be stated plainly: a biologics license application submitted in the first half of 2027 would be a company objective met, and the review that follows has its own timeline and its own risk of a complete response. The Regenerative Medicine Advanced Therapy designation granted in June 2026 gives the program intensive agency interaction and the possibility of expedited review; it does not shorten the evidence required. Form 10-Q, September 30, 2026
04 PM577a and Wilson disease: the most common mutation, in the largest market
Wilson disease is a genetic disorder of copper metabolism caused by variants in ATP7B, in which copper accumulates in the liver and later in the brain. Tang et al., Orphanet Journal of Rare Diseases 2026 The H1069Q variant that PM577a targets is described by the company as the most prevalent disease-causing mutation in the United States and Europe, which is why it is the first allele the program addresses. The company received clearance of a clinical trial application in New Zealand in June 2026 and of an investigational new drug application from the Food and Drug Administration in July 2026, and reported in October 2026 that the first patient had been dosed in the global Phase 1/2 trial. A follow-on candidate targeting R778L, the most common mutant allele in East Asian populations, is in preclinical development. Form 10-Q, September 30, 2026
The clinical logic is straightforward and the practical logic is not. Existing treatment relies on chelating agents and zinc, which manage copper balance rather than correct the underlying defect, and adherence is a persistent problem because the regimens are lifelong and unpleasant. A one-time or infrequent correction would be a genuine advance if it worked. Against that, Wilson disease has a functioning standard of care, so a new therapy must show not only that it edits but that it improves on decades of chelation with an acceptable safety profile, and it must do so in patients whose disease may already be advanced. Tang et al., Orphanet Journal of Rare Diseases 2026
The trial design question that will shape the 2027 readout is what the company measures. Sequence-level editing in a liver biopsy is the mechanistic endpoint; copper handling, urinary copper, liver enzymes and clinical stability are the disease endpoints. A program that reports editing without a disease signal leaves the commercial question open, and one that reports disease improvement without durable editing raises the question of how long the effect lasts. Those are different forms of good news and the market tends to price them the same way. Form 10-Q, September 30, 2026
05 PM647 and alpha-1 antitrypsin deficiency: a large genotype, a difficult protein
Alpha-1 antitrypsin deficiency is caused by mutations in SERPINA1. The Pi*Z allele, produced by the E342K substitution, leads to a misfolded protein that accumulates in liver cells and is secreted at low levels, producing both liver disease and, in the lung, emphysema from unchecked protease activity. The company says approximately 100,000 people in the United States carry the PiZZ genotype and that PM647 is designed to correct the E342K mutation. The Food and Drug Administration cleared the investigational new drug application in September 2026, enabling a global Phase 1/2 study starting in the United States, with initial clinical data expected in 2027. Form 10-Q, September 30, 2026
The biology sets a higher bar than Wilson disease in one respect and a lower one in another. Correcting the Pi*Z variant should reduce the misfolded protein that damages the liver and increase circulating alpha-1 antitrypsin, so the effect is measurable in blood — a simpler readout than a liver biopsy. But the protein must reach a threshold to matter clinically, and augmentation therapy with plasma-derived protein already exists for the lung component, which means PM647 has to compete against an established, if imperfect, standard. Screening is also a practical obstacle: many carriers are undiagnosed, and the 2026 literature on detection scores exists precisely because identifying Pi*Z patients is a bottleneck. Cheng et al., Genetics in Medicine 2026
For a platform argument, PM647 carries more weight than its commercial size suggests. It uses the same liver nanoparticle as PM577a with a different editor payload, so a working PM647 is direct evidence that the delivery system is modular in patients and not only in mice. A failure confined to one program would be serious; a failure that appears in both, at the level of delivery or immunogenicity, would be a statement about the platform. Form 10-Q, September 30, 2026
06 PM359 and the ex vivo proof: the program with human data and the smallest market
PM359 is the program edited outside the body, in hematopoietic stem cells, for chronic granulomatous disease — an inherited immune defect in which phagocytes cannot kill certain bacteria and fungi. The company is in regulatory dialogue toward a biologics license application planned for the first half of 2027 and received Regenerative Medicine Advanced Therapy designation in June 2026. The designation brings intensive guidance and the potential for expedited review, and it is granted on the basis of preliminary clinical evidence that the product may address an unmet need. Form 10-Q, September 30, 2026
The strategic role of PM359 is credibility, not revenue. If it reaches a filing and an approval, it demonstrates that a Prime Edited cell product can be manufactured, tested and accepted by a regulator, which is the part of the platform that the technology papers do not settle. It would also give the company a commercial operation, however small, and a template for other ex vivo programs. What it cannot do is prove that in vivo delivery works, because the edited cells in PM359 are modified outside the patient under conditions a lipid nanoparticle never faces. The two halves of the platform share an editor and nothing else of clinical importance. Form 10-Q, September 30, 2026
The burden of a filing is also routinely underestimated. A biologics license application requires comparability across manufacturing lots, potency assays that predict clinical effect, and a safety database sized to the indication. For a first-in-class edited cell therapy those requirements are where programs lose years, and the company’s own language has stayed at the level of dialogue toward a planned submission. Form 10-Q, September 30, 2026
07 Cystic fibrosis and the BMS CAR-T work: options that cost money today
Two programs sit outside the liver and the blood. The in vivo cystic fibrosis program is supported by the Cystic Fibrosis Foundation, which shifts part of the cost to a nonprofit funder and gives the program a patient-community constituency. The Prime Edited CAR-T work is conducted in partnership with Bristol-Myers Squibb through Juno Therapeutics, and it is the source of essentially all of the company’s reported revenue: $4.213 million in the third quarter of 2026 and $6.223 million in the nine months, all of it collaboration revenue and all of it from the BMS/Juno agreement; there was no non-related-party revenue in the quarter. Deferred revenue from that agreement stood at $8.977 million current and $50.777 million non-current at September 30, 2026. Form 10-Q, September 30, 2026
Revenue of this kind should be read carefully. Collaboration revenue is recognised as performance obligations are satisfied, so the deferred balance is work still owed rather than money still to come, and the cash associated with it was received earlier. The partnership is valuable because a large pharmaceutical company validated the editing approach with a contract and because milestone payments can arrive without issuing equity. It is not a commercial business: the company states that it has generated no product revenue and does not expect any for the foreseeable future. Form 10-Q, September 30, 2026
The strategic question for these two programs is prioritisation under a fixed budget. A company with one delivery platform and a 2027 deadline for two liver readouts and one filing has to decide what the cystic fibrosis and CAR-T work are for. If they generate milestones and partner funding, they pay for themselves and keep an option. If they consume internal research capacity without near-term value, they are the first place a cost reduction would land, and the research budget is already the largest single item the company controls. Form 10-Q, September 30, 2026
08 The November offering: $143.7 million gross, and a bigger denominator
Prime Medicine priced an underwritten offering on November 10, 2026 and closed it two days later. The base deal was 35,714,286 shares at $3.50; the underwriters’ option for 5,357,142 more was exercised in full, so the company sold 41,071,428 shares for gross proceeds of about $143.7 million and net proceeds of about $134.7 million, after about $9.1 million of underwriting discounts, commissions and offering costs. Jefferies, TD Cowen and Goldman Sachs acted as joint book-running managers, with Oppenheimer and LifeSci Capital as passive book-running managers. Final prospectus supplement, November 12, 2026
The price is the part that matters most for existing holders. The shares were priced at $3.50 in the underwriting agreement of November 10, 2026, and the offering added 41.1 million shares to a base of 181.9 million reported at October 31 — roughly 22.6 per cent dilution in a single transaction (Merlintrader arithmetic from the two figures). The company intends to use the net proceeds, together with existing cash, primarily to advance the Wilson disease and alpha-1 antitrypsin deficiency programs and other research, with the remainder for working capital and general corporate purposes. Final prospectus supplement, November 12, 2026
The timing tells its own story. A company that raises capital ahead of its 2027 liver readouts is buying runway on the market’s terms rather than waiting for its own data to improve them, and the proceeds answer the question the going-concern paragraph raised: without this money, the twelve-month horizon was not covered. The offering removes the immediate financing question and leaves the more important one — whether the 2027 data justify what was paid to reach them. Form 8-K, November 12, 2026
09 Prime Medicine earnings: a narrower loss and the cost of two Phase 1/2 studies
The third quarter of 2026 produced revenue of $4.213 million, all of it collaboration revenue and $4.167 million of it from the related party agreement. Research and development expense was $34.117 million against $43.990 million a year earlier, and general and administrative expense was $10.022 million against $11.208 million, taking total operating expenses to $44.139 million from $55.198 million. Other income of $883 thousand, mainly interest and accretion on investments, brought the net loss to $39.043 million, or $0.22 per share, against $50.582 million and $0.32 a year earlier. Form 10-Q, September 30, 2026
The nine-month picture shows the same direction with a different shape. Revenue was $6.223 million against $3.794 million, research and development fell to $101.619 million from $125.927 million, general and administrative expense rose slightly to $38.469 million from $37.609 million, and the net loss narrowed to $130.274 million from $155.063 million, or $0.73 per share against $1.11. The reduction in research spending is not a sign of a smaller ambition; it follows the 2025 restructuring that concentrated the company on the liver programs and the ex vivo product, and it is the reason the loss is narrowing while the pipeline narrows with it. Form 10-Q, September 30, 2026
Two structural facts sit under the income statement. The company has an accumulated deficit of $1,018.6 million, which is the accumulated cost of building the platform, and it states that it expects operating losses and negative operating cash flow for the foreseeable future. Revenue from the collaboration is recognised over the performance period, so it moves with the work done rather than with cash received, and it will decline as the deferred balance of $59.8 million is consumed unless new agreements replace it. Form 10-Q, September 30, 2026
10 Cash, burn and the runway after the offering
At September 30, 2026 the company held $54.886 million of cash and cash equivalents and $6.271 million of short-term investments, $61.157 million of unrestricted liquidity, plus $13.691 million of restricted cash that cannot be spent on development. Operating activities used $120.439 million in the nine months, which is about $13.38 million a month on average (Merlintrader arithmetic from the cash-flow statement), and about $36.683 million in the third quarter alone (Merlintrader arithmetic between the nine-month and first-half cash-flow statements). On the September balance, before the offering, that historical rate corresponded to roughly four and a half months. Form 10-Q, September 30, 2026
Adding the November net proceeds of about $134.7 million and the restricted cash gives the approximately $209.5 million of pro forma resources the company described, and with it the guidance that resources fund operating expenses and capital expenditures through 2027. That guidance is a statement about the end of 2027, not about the second half of 2027: two Phase 1/2 studies reporting during 2027, a biologics application being prepared in the first half, and a burn near $13 million a month mean the margin is measured in quarters rather than years. Third-quarter release, November 12, 2026
The going-concern conclusion deserves a note of its own because it survives the offering. The Form 10-Q, filed the same day the offering closed, states that management concluded substantial doubt exists about the ability to continue as a going concern for twelve months from the issuance of the financial statements, and explains that the mitigating actions — raising capital through equity or other financing — are outside the company’s control and therefore cannot be counted under the accounting standard until they happen. The proceeds were received after the balance-sheet date; the statement describes the position at filing. Form 10-Q, September 30, 2026
11 Share dilution: what the offering added to an already large count
The common share count is unusually large for a company at this stage, and that is the result of repeated raises. The Form 10-Q cover reports 181,921,405 shares outstanding at October 31, 2026, before the November offering; the prospectus supplement used 180,737,548 shares at June 30 for its net tangible book value calculation, which was approximately $39.8 million, or $0.22 per share. Adding 41,071,428 shares brings the count to roughly 223 million, against a net tangible book value per share that the offering itself lowered. Final prospectus supplement, November 12, 2026
Behind the outstanding shares sit instruments that will add more. The prospectus lists time-based and vested performance-based options with a weighted average exercise price of $3.66 as of June 30, 2026, and 3,472,546 shares issuable on the vesting of performance-based awards. At a share price near the offering price those options are in the money and represent real dilution when exercised, and the performance awards convert if the clinical milestones they are tied to are met — which means the dilution arrives with the good news. Final prospectus supplement, November 12, 2026
The practical consequence is that a per-share calculation of any future success has to use a denominator near 223 million, not the 160 million that was the weighted average in the third quarter of 2025. The company’s own convention supports that reading: the weighted average for the nine months of 2026 was 177.4 million, and the offering moved the count beyond it. A platform that succeeds commercially will be divided among about a quarter more shares than the 177.4 million weighted average of the first nine months of 2026, and about forty per cent more than the 160.5 million weighted average of the third quarter of 2025. Form 10-Q, September 30, 2026
12 Ownership, short interest and the people running the plan
Short interest was 29.15 million shares at the October 30, 2026 settlement, with 4.80 days to cover, a position that is large in absolute terms and modest relative to the 181.9 million shares reported outstanding at October 31, 2026. On a name that trades on data timing, positioning of that size can amplify reactions in either direction, and its direction should not be read as a view on the science. Nasdaq short interest, October 30, 2026 settlement
The management history matters for how the strategy should be read. Allan Reine succeeded Keith Gottesdiener as chief executive on May 19, 2025, when Jeff Marrazzo became executive chair, and Svetlana Makhni’s appointment as chief financial officer was approved on April 7, 2026 and took effect on April 16, after which Reine ceased to serve as principal financial officer while remaining chief executive. A chief executive who arrived with a restructuring mandate has since narrowed the pipeline, cut research spending and raised capital twice; the 2026 sequence is consistent with that mandate rather than a change of direction. Form 10-Q, September 30, 2026
Ownership is diffuse. Two schedule filings dated November 13, 2026 report positions under the 5 per cent reporting framework rather than a control bloc: Schedule 13D/A and Schedule 13G. No single holder can impose a strategy, and management’s accountability runs through the board and the next financing rather than through a dominant investor. EDGAR Schedule 13 filings
13 Red flags and the overall assessment
Four red flags are worth stating plainly. First, the company has never earned product revenue and does not expect to for years, while its cost base is sized for a platform; the narrowing of research spending is what keeps the loss from growing. Second, the November offering added more than a fifth to the share count at a contractual price of $3.50, which is what a company pays when it needs capital before its data arrive. Third, the going-concern paragraph is in the filing submitted on the day the offering closed: the financing fixed the next twelve months, not the business model. Fourth, the platform’s central claim — that the same liver nanoparticle can carry different editors — has not yet been demonstrated in patients, and both proof points land in the same year. Form 10-Q, September 30, 2026
The overall assessment is that Prime Medicine now has what a platform company needs to be judged on evidence rather than on promises: cleared applications for two liver programs, a dosed first patient, an ex vivo program approaching a filing, and enough money to reach 2027. What it does not have is a single human result showing that in vivo Prime Editing works at a therapeutic level. The company has been reorganized around that question, financed to answer it, and scheduled the answer for the same twelve months in which it must also file for PM359. That concentration of events is the investment case and the risk, in the same sentence. Form 10-Q, September 30, 2026
Merlintrader Health Score · $PRME
2.50out of 5
Assessed October 2, 2026; reassessed November 10, 2026, after the preliminary September 30 cash estimate and the proposed offering (capital allocation lowered from 2.0 to 1.5), on November 11 and 12 after the pricing and the final prospectus supplement (scores unchanged), and again on November 12, 2026, after the closing of the offering and the Q3 Form 10-Q (financial resources raised from 1.5 to 2.0); reviewed November 16, 2026, after the scheduled Jefferies fireside chat, an investor appearance with no new data or financing announced, and on November 22, 2026: scores unchanged. Weighted calculation: 2.0×30% + 3.5×30% + 1.5×20% + 3.0×10% + 2.5×10% = 2.50. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.
Red flags
- The adverse case combines weak or delayed clinical progress with unfavorable access to capital. In the September 30, 2026 financial statements, nine-month operating cash use of $120.439 million implies a historical monthly burn of approximately $13.38 million (Merlintrader arithmetic). This is a calculated historical average, not a forecast; it nonetheless shows why a delay in a 2027 data window could matter financially. The $13.691 million of restricted cash reported separately at September 30 cannot simply be added to unrestricted development funding.
- The offering closed on November 12, 2026 issued 41,071,428 new shares at $3.50, including the full underwriter option, diluting existing holders.
- Unrestricted liquidity fell to $61.157 million at September 30 from $95.071 million at June 30, and the Q3 Form 10-Q still concludes substantial doubt about going concern despite the November offering.
- Company forecasts depend on execution and may change.
- Financial balances retain their stated reporting date; later financing is separate.
- Investment involves possible loss of part or all of the capital.
PRME Stock FAQ: Prime Medicine Questions Answered
When will Prime Medicine report its next clinical results?
As of November 12, 2026, Prime Medicine guides initial PM577a and PM647 clinical data to 2027, without exact release dates. Its August update separately targets a PM359 biologics license application in H1 2027. These are company development windows; a filing target is not an FDA decision date. Development windows. PM647 update. PM577a clinical update. Chief Executive Officer Allan Reine was scheduled for a fireside chat at the Jefferies Global Healthcare Conference in London on November 16, 2026, at 11:00 a.m. ET; it was an investor appearance, not a clinical data release, and as of November 16 the company had not announced another dated event. Jefferies fireside chat.
Are Prime Medicine’s PM359 and PM647 FDA approved?
No: as of November 12, 2026, these remain investigational programs. PM647 received FDA IND clearance on September 24, 2026, within its previously guided third-quarter window and allowing clinical study. PM359 has RMAT designation and a targeted application submission, rather than marketing approval. PM647 clinical clearance. PM359 regulatory status.
How much cash does Prime Medicine have, and how long will it last?
Prime Medicine reported $61.157 million of cash, cash equivalents and short-term investments at September 30, 2026, plus $13.691 million of restricted cash, after nine-month operating cash use of $120.439 million. On November 12 it closed an offering of 41,071,428 shares at $3.50, including the full underwriter option, for about $143.7 million gross and $134.7 million net; it puts pro forma cash, investments and restricted cash at about $209.5 million and expects to fund operations through 2027. The September 30 Form 10-Q still states substantial doubt about going concern. Third-quarter release and funding guidance. September 30 Form 10-Q. Offering pricing.
Is PRME stock at risk of dilution?
Yes: by November 12, 2026, Prime Medicine had closed an underwritten offering, with the underwriters’ option exercised in full, for $143.7 million of gross proceeds and about $134.7 million net. Third-quarter release. The offering priced 35,714,286 shares plus up to 5,357,142 option shares at $3.50; with the full option, 221,808,976 shares would be outstanding after the offering, based on the June 30, 2026 count. Final prospectus supplement. Prime Medicine also has an at-the-market program, depends on further financing and reports substantial doubt about its ability to continue as a going concern; future equity sales and stock awards can add dilution. September 30 Form 10-Q.
When does Prime Medicine report earnings?
Prime Medicine reported third-quarter 2026 results on November 12, 2026, for the quarter ended September 30, and filed its Form 10-Q the same day; as of that date it had not announced the date of its next financial results. Its clinical-data windows are separate from the financial reporting schedule. Latest quarterly results. September 30 Form 10-Q.
What does Prime Medicine do?
Prime Medicine develops gene-editing therapies using its Prime Editing platform. Its investigational pipeline includes PM577a for a specific Wilson disease mutation, PM647 for alpha-1 antitrypsin deficiency and PM359, an edited autologous blood stem-cell therapy for chronic granulomatous disease. Its programs are in clinical development. Company pipeline.
Has Prime Medicine started treating Wilson disease patients with PM577a?
Yes: Prime Medicine announced the first patient dosed in its PM577a Phase 1/2 trial on October 5, 2026. The open-label dose-escalation study evaluates safety, tolerability and preliminary efficacy in H1069Q-mutated Wilson disease. Initial clinical data are expected in 2027; starting treatment is not itself an efficacy result. First patient dosed.
Did Prime Medicine insiders buy stock in the April and June 2026 filings?
No: Prime Medicine’s April 16 and June 5, 2026 disclosures for Svetlana Ni Makhni and David Schenkein describe compensatory option awards coded A in Forms 4. Those specific awards were compensation, rather than discretionary open-market purchases with personal cash. April option award. June option award.
Primary sources
- November 12, 2026 — Third-quarter 2026 results: offering closed with full option exercise ($143.7 million gross, $134.7 million net), pro forma resources of about $209.5 million, runway through 2027
- November 12, 2026 — Form 10-Q for the quarter ended September 30, 2026: cash, going-concern assessment, 181,921,405 shares at October 31
- November 12, 2026 (dated November 10) — Final prospectus supplement: 35,714,286 shares at $3.50, estimated net proceeds of about $117.1 million, 216,451,834 shares outstanding after the offering
- November 12, 2026 — Form 8-K, Item 1.01: underwriting agreement with Jefferies, TD Securities and Goldman Sachs; closing expected on or about November 12
- November 10, 2026 — Prime Medicine announces pricing of its public offering: 35,714,286 shares at $3.50, about $125.0 million gross, closing expected on or about November 12
- November 10, 2026 — Preliminary prospectus supplement: proposed $125.0 million common-stock offering, underwriter option and use of proceeds
- November 10, 2026 — Form 8-K: preliminary September 30, 2026 cash estimate and November corporate presentation
- November 9, 2026 — Prime Medicine to present at the Jefferies Global Healthcare Conference, November 16
- 1. Form 10-Q — June 30, 2026; filed August 6, 2026
- 2. Form 10-K — December 31, 2025; filed March 3, 2026
- 3. PM647 FDA IND clearance — September 24, 2026
- 4. Second-quarter financial results and pipeline update — August 6, 2026
- 5. PM577a FDA IND clearance — July 23, 2026
- 6. Binding Beam arbitration resolution — July 8, 2026
- 7. PM359 clinical results and NEJM publication — December 7, 2025
- 8. Prime Editing for p47phox-deficient CGD — NEJM; online December 7, 2025
- 9. 2026 proxy — March 31, 2026 beneficial ownership basis
- 10. Svetlana Ni Makhni Form 4 — April 17, 2026
- 11. David Schenkein Form 4 — June 8, 2026
- 13. Prime Medicine — first patient dosed in the Phase 1/2 trial of PM577a, October 5, 2026
- October 5, 2026 — First patient dosed with PM577a in Wilson disease
- September 24, 2026 — PM647 receives FDA IND clearance
- August 6, 2026 — Runway and PM359 filing guidance
- July 23, 2026 — PM577a cleared for US testing
- July 8, 2026 — Beam arbitration resolves a specific obstacle
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent analysis and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $PRME or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.



